These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30819188)

  • 1. Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2019 Feb; 18(1):19. PubMed ID: 30819188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
    Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M; Carlson CJ
    BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
    Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
    Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
    Hanssen NM; Jandeleit-Dahm KA
    Diab Vasc Dis Res; 2019 Jul; 16(4):303-309. PubMed ID: 31018682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH; Udell JA; Filion KB
    Trends Cardiovasc Med; 2017 Apr; 27(3):194-202. PubMed ID: 28291655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
    Zhang DP; Xu L; Wang LF; Wang HJ; Jiang F
    Cardiovasc Diabetol; 2020 Jan; 19(1):10. PubMed ID: 31969144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?
    Testani JM; Inzucchi SE; Voors AA
    Circulation; 2019 May; 139(21):2383-2385. PubMed ID: 31107618
    [No Abstract]   [Full Text] [Related]  

  • 10. Report from the 5th cardiovascular outcome trial (CVOT) summit.
    Schnell O; Standl E; Cos X; Heerspink HJ; Itzhak B; Lalic N; Nauck M; Ceriello A
    Cardiovasc Diabetol; 2020 Apr; 19(1):47. PubMed ID: 32303223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
    Ludwig L; Darmon P; Guerci B
    Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging glucose-lowering therapies: a guide for cardiologists.
    Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
    Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
    Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):422-427. PubMed ID: 31064213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know?
    Pagidipati NJ; Lopes RD
    J Thorac Cardiovasc Surg; 2019 Oct; 158(4):1113-1117. PubMed ID: 31301898
    [No Abstract]   [Full Text] [Related]  

  • 17. Are We Ready to Bell The Cat? A Call for Cardiologists to Embrace Glucose-Lowering Therapies Proven to Improve Cardiovascular Outcomes.
    Nassif ME; Kosiborod M
    Circulation; 2018 Jul; 138(1):4-6. PubMed ID: 29967227
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin resistance: Impact on therapeutic developments in diabetes.
    Bailey CJ
    Diab Vasc Dis Res; 2019 Mar; 16(2):128-132. PubMed ID: 31014100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in adults with type 2 diabetes mellitus starting with new glucose lowering drugs: An inception cohort study.
    Torre C; Guerreiro J; Longo P; Raposo JF; Leufkens H; Martins AP
    Prim Care Diabetes; 2019 Jun; 13(3):221-232. PubMed ID: 30573348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.